U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07447986) titled 'To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus' on Feb. 25.
Brief Summary: This was a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study. The primary objective was to evaluate the efficacy of SG301 SC injection in participants with systemic lupus erythematosus (SLE) based on the SRI-4 response rate. The secondary objectives were to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity profiles of SG301 SC injection in participants with SLE.
Study Start Date: March 15
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus (SL...